NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free DCTH Stock Alerts $7.07 +1.67 (+30.93%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$5.96▼$7.3550-Day Range$3.72▼$7.0752-Week Range$2.25▼$7.99Volume1.59 million shsAverage Volume229,347 shsMarket Capitalization$196.40 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside180.1% Upside$19.80 Price TargetShort InterestBearish3.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 15 Articles This WeekInsider TradingAcquiring Shares$100,001 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.45) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.07 out of 5 starsMedical Sector373rd out of 928 stocksSurgical & Medical Instruments Industry54th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.34% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Delcath Systems has recently increased by 13.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 3.0 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Delcath Systems this week, compared to 2 articles on an average week.Search Interest12 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows5 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.45) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 9.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesMay 15 at 6:18 AM | americanbankingnews.comDelcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Increase in Short InterestMay 15 at 3:52 AM | finance.yahoo.comDelcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 15 at 1:27 AM | msn.comStephens & Co. Initiates Coverage of Delcath Systems (DCTH) with Overweight RecommendationMay 14 at 9:59 AM | markets.businessinsider.comDelcath Systems Inc. Q1 Loss Beats EstimatesMay 14 at 7:30 AM | prnewswire.comDelcath Systems Reports First Quarter 2024 Results and Business HighlightsMay 13 at 11:59 PM | markets.businessinsider.comDelcath Systems Poised for Commercial Success with HEPZATO-KIT Launch, Analyst Issues Buy RatingMay 12 at 3:01 AM | americanbankingnews.comDelcath Systems (DCTH) to Release Earnings on TuesdayMay 7, 2024 | prnewswire.comDelcath Systems to Host First Quarter 2024 Earnings CallMay 6, 2024 | prnewswire.comPublication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KITMay 3, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finance.yahoo.comDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)March 27, 2024 | finance.yahoo.comDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comDelcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic AdvancementsMarch 26, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 26, 2024 | msn.comDelcath Systems GAAP EPS of -$0.48, revenue of $0.54MMarch 26, 2024 | prnewswire.comDelcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 25, 2024 | msn.comDelcath Systems Q4 2023 Earnings PreviewMarch 23, 2024 | finance.yahoo.comInsiders of Delcath Systems Getting Good Value On Their US$736.5k InvestmentMarch 20, 2024 | prnewswire.comDelcath Systems Closes $7 Million Private PlacementMarch 19, 2024 | prnewswire.comDelcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update CallMarch 19, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 18, 2024 | markets.businessinsider.comDelcath Systems Appoints Martha Rook As COOMarch 18, 2024 | prnewswire.comDelcath Systems Appoints Martha S. Rook as Chief Operating OfficerSee More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/14/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees76Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+161.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,680,000.00 Net Margins-2,308.86% Pretax Margin-2,308.86% Return on Equity-563.60% Return on Assets-111.13% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.06 Sales & Book Value Annual Sales$2.07 million Price / Sales94.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book9.82Miscellaneous Outstanding Shares27,780,000Free Float22,800,000Market Cap$196.40 million OptionableOptionable Beta0.55 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $727.97kMs. Sandra Pennell (Age 44)Senior VP of Finance and Principal Financial & Accounting Officer Dr. Martha S. Rook Ph.D. (Age 54)Chief Operating Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Johnny John M.D. (Age 59)Senior Vice President of Clinical Operations & Medical Affairs Comp: $472.16kDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsProfound MedicalNASDAQ:PROFOrchestra BioMedNASDAQ:OBIOAlpha Tau MedicalNASDAQ:DRTSQuipt Home MedicalNASDAQ:QIPTAVITA MedicalNASDAQ:RCELView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 161,678 shares on 5/10/2024Ownership: 2.461%Vivo Capital LLCBought 811,555 shares on 4/22/2024Ownership: 6.552%Gil AharonBought 26,882 shares on 3/19/2024Total: $100,001.04 ($3.72/share)Gerard J MichelBought 34,000 shares on 12/8/2023Total: $99,960.00 ($2.94/share)Rosalind Advisors, Inc.Bought 100,000 shares on 11/17/2023Total: $240,000.00 ($2.40/share)View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for Delcath Systems' stock. Their DCTH share price targets range from $13.00 to $25.00. On average, they anticipate the company's stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 180.1% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2024? Delcath Systems' stock was trading at $4.16 on January 1st, 2024. Since then, DCTH shares have increased by 70.0% and is now trading at $7.07. View the best growth stocks for 2024 here. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) posted its earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.19. The company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same quarter in the prior year, the firm earned ($0.86) EPS. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by a number of retail and institutional investors. Top institutional investors include Vivo Capital LLC (6.55%), Vanguard Group Inc. (2.46%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHow to Make 100X on the AI BoomInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
